- Home
- AYTU vs EDSA Comparison
AYTU vs EDSA Comparison
Compare AYTU & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYTU
- EDSA
- Stock Information
- Founded
- AYTU N/A
- EDSA 2015
- Country
- AYTU United States
- EDSA Canada
- Employees
- AYTU N/A
- EDSA N/A
- Industry
- AYTU Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- AYTU Health Care
- EDSA Health Care
- Exchange
- AYTU Nasdaq
- EDSA Nasdaq
- Market Cap
- AYTU 9.6M
- EDSA 13.8M
- IPO Year
- AYTU N/A
- EDSA N/A
- Fundamental
- Price
- AYTU $2.18
- EDSA $2.03
- Analyst Decision
- AYTU Strong Buy
- EDSA Strong Buy
- Analyst Count
- AYTU 1
- EDSA 2
- Target Price
- AYTU $12.00
- EDSA $13.00
- AVG Volume (30 Days)
- AYTU 624.8K
- EDSA 33.4K
- Earning Date
- AYTU 05-14-2025
- EDSA 08-08-2025
- Dividend Yield
- AYTU N/A
- EDSA N/A
- EPS Growth
- AYTU N/A
- EDSA N/A
- EPS
- AYTU N/A
- EDSA N/A
- Revenue
- AYTU $81,659,000.00
- EDSA N/A
- Revenue This Year
- AYTU N/A
- EDSA N/A
- Revenue Next Year
- AYTU $8.68
- EDSA N/A
- P/E Ratio
- AYTU N/A
- EDSA N/A
- Revenue Growth
- AYTU 0.41
- EDSA N/A
- 52 Week Low
- AYTU $0.95
- EDSA $1.55
- 52 Week High
- AYTU $2.96
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- AYTU 63.85
- EDSA 52.89
- Support Level
- AYTU $2.04
- EDSA $1.91
- Resistance Level
- AYTU $2.17
- EDSA $2.14
- Average True Range (ATR)
- AYTU 0.15
- EDSA 0.12
- MACD
- AYTU 0.00
- EDSA 0.02
- Stochastic Oscillator
- AYTU 56.86
- EDSA 64.52
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.